Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 253

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Interleukin-23 engineering improves CAR T cell function in solid tumors

Open access
Ma, Xingcong, Shou, Peishun, Smith, Christof, Chen, Yuhui, Du, Hongwei, Sun, Chuang, Porterfield Kren, Nancy, Michaud, Daniel, Ahn, Sarah, Vincent, Benjamin, Savoldo, Barbara, Pylayeva-Gupta, Yuliya, Zhang, Shuqun, Dotti, Gianpietro, Xu, Yang·2020·Nature Biotechnology

Abstract

Cytokines that stimulate T cell proliferation, such as interleukin (IL)-15, have been explored as a means of boosting the antitumor activity of chimeric antigen receptor (CAR) T cells. However, constitutive cytokine signaling in T cells and activation of bystander cells may cause toxicity. IL-23 is a two-subunit cytokine known to promote proliferation of memory T cells and T helper type 17 cells. We found that, upon T cell antigen receptor (TCR) stimulation, T cells upregulated the IL-23 receptor and the IL-23α p19 subunit, but not the p40 subunit. We engineered expression of the p40 subunit in T cells (p40-Td cells) and obtained selective proliferative activity in activated T cells via autocrine IL-23 signaling. In comparison to CAR T cells, p40-Td CAR T cells showed improved antitumor capacity in vitro, with increased granzyme B and decreased PD-1 expression. In two xenograft and two syngeneic solid tumor mouse models, p40-Td CAR T cells showed superior efficacy in comparison to CAR T cells and attenuated side effects in comparison to CAR T cells expressing IL-18 or IL-15. The efficacy of chimeric antigen receptor (CAR) T cells in solid tumor models is enhanced by interleukin-23 engineering.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41587-019-0398-2

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 253

Metadata

Authors
Ma, X., Shou, P., Smith, C., Chen, Y., Du, H., Sun, C., Porterfield Kren, N., Michaud, D., Ahn, S., Vincent, B., Savoldo, B., Pylayeva-Gupta, Y., Zhang, S., Dotti, G., & Xu, Y.
Venue
Nature Biotechnology
Published
2020-02-03
Volume
38
Issue
4
Pages
448-459
ISSN
  • 0733-222X (ISSN-L)
  • 1087-0156
  • 1546-1696
OpenAlex
W3003850371
Cited by
253
References
66
FWCI
11.87
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin-23 engineering improves CAR T cell function in solid tumors. https://app.cochat.ai/papers/10.1038/s41587-019-0398-2
The paper
Ma, X., Shou, P., Smith, C., Chen, Y., Du, H., Sun, C., Porterfield Kren, N., Michaud, D., Ahn, S., Vincent, B., Savoldo, B., Pylayeva-Gupta, Y., Zhang, S., Dotti, G., & Xu, Y. (2020). Interleukin-23 engineering improves CAR T cell function in solid tumors. Nature Biotechnology. https://doi.org/10.1038/s41587-019-0398-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.